Progress of multidisciplinary treatment of intrahepatic cholangiocarcinoma
10.3760/cma.j.issn.1673-4203.2020.02.011
- VernacularTitle: 肝内胆管细胞癌的多学科综合治疗进展
- Author:
Zheng LIU
1
;
Feihong ZHANG
1
;
Zhenggang XU
1
;
Ke WANG
1
Author Information
1. Department of Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University; Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences; NHC Key Laboratory of Living Donor Liver Transplantation, Nanjing 210029, China
- Publication Type:Review
- Keywords:
Bile duct neoplasms;
Therapeutic uses;
Intrahepatic cholangiocarcinoma;
Multidisciplinary treatment
- From:
International Journal of Surgery
2020;47(2):122-126
- CountryChina
- Language:Chinese
-
Abstract:
Intrahepatic cholangiocellular carcinoma (ICC) has become the second common malignant tumors of the liver, with its incidence being next only to hepatocellular carcinoma (HCC). Due to the lack of targeted screening methods and specific clinical manifestations, most intrahepatic cholangiocarcinoma(ICC)is clearly diagnosed as advanced, which brings great difficulties to the treatment of ICC. At present, radical surgical resection is still the most effective method to ICC. However, for some patients who had a positive-margin (R1) resection or positive lymph node metastasis, multidisciplinary comprehensive treatment including transcatheter arterial chemoembolization (TACE), local ablation, systemic chemotherapy, targeted therapy and immunotherapy, etc. can effectively improve the prognosis of these patients.
